Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Currently submitted to: JMIR Formative Research

Date Submitted: Apr 18, 2026
Open Peer Review Period: Apr 22, 2026 - Jun 17, 2026
(currently open for review)

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Willingness of Chemotherapy Patients and Healthcare Providers to Digitally Manage Chemotherapy-induced Nausea and Vomiting in Western China

  • Fang Li; 
  • Yufeng Liu; 
  • Xiaoyu Liu; 
  • Xi Luo; 
  • Ye Yang; 
  • Min Zheng; 
  • Xiaoling Liu; 
  • Gunfen Wang; 
  • Qin Zhou

ABSTRACT

Background:

Chemotherapy-induced nausea and vomiting (CINV) is one of the most common and distressing symptoms experienced by chemotherapy patients. The digital symptom management model has demonstrated positive effects in high-income countries. However, its application remains in the exploratory phase in the western region of China.

Objective:

This study aims to explore the willingness of both cancer patients and healthcare providers on digital management of CINV in the western region of China.

Methods:

In this cross - sectional study, questionnaires were distributed to 271 cancer patients who had undergone chemotherapy and 116 healthcare providers from tertiary hospitals in Western China. The survey aimed to assess the willingness of both chemotherapy patients and healthcare providers on digital management of CINV. The survey evaluated the willingness of both chemotherapy patients and healthcare providers regarding digital management of CINV, including preferences for follow - up methods, challenges faced, and attitudes toward digital tools.

Results:

Nearly half of the patients(48%) reported that CINV was the most uncomfortable symptom they experienced during chemotherapy. Among discharged patients, 41% continued to experienced CINV, and 37.8% of them did not take any measures to manage their CINV. A majority (62.9%) of patients preferred weekly follow - up, with manual telephone calls and WeChat mini - programs being the most preferred modes of follow - up (85.6% and 59.1%, respectively). Both physicians and nurses agreed that follow - up monitoring and intervention during in-hospital and post - discharge periods were critical for CINV management. Time constraints were identified as a major challenge in managing CINV, with 50.7% of nurses willing to spend 15 to 30 minutes daily, and 66.7% of physicians willing to allocate 0 to 15 minutes daily for CINV management.

Conclusions:

Both patients and healthcare providers expressed strong support for improved management of CINV, and digital management tools may offer a promising solution to enhance the effectiveness of CINV managemen. However, overcoming time constraints and aligning digital solutions with clinical workflows are crucial for successful implementation. Clinical Trial: No. SCCHEC-02-2024-242


 Citation

Please cite as:

Li F, Liu Y, Liu X, Luo X, Yang Y, Zheng M, Liu X, Wang G, Zhou Q

Willingness of Chemotherapy Patients and Healthcare Providers to Digitally Manage Chemotherapy-induced Nausea and Vomiting in Western China

JMIR Preprints. 18/04/2026:98732

DOI: 10.2196/preprints.98732

URL: https://preprints.jmir.org/preprint/98732

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.